The plant alkaloid galantamine: Approved as a drug; sold as a supplement

Alternative and Complementary Therapies

Volumn 7, Issue 6, 2001, Pages 380-383

  Cronin, J R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; SABELUZOLE;

ALZHEIMER DISEASE; DRUG APPROVAL; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; REVIEW;

EID: 0035205816     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/10762800152709741     Document Type: Review

References (22)

1. A review of the acetylcholinesterase inhibitor galanthamine
2. Potent acetylcholinesterase inhibitors: Design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series
3. The pharmacology of galanthamine and its analogues
4. Structure of acetyl-cholinesterase complexed with galanthamine at 2.3 Angstrom resolution
5. Amyloid beta-protein and the genetics of Alzheimer's disease
6. Alzheimer neurofibrillary lesions: Molecular nature and potential roles of different components
7. The cortical neuritic dystrophy of Alzheimer's disease: Nature significance, and possible pathogenesis
8. Free radical formation in autopsy samples of Alzheimer and control cortex
9. The molecular pathology of Alzheimer's disease
10. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia
11. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy
12. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease
13. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
14. Nivalin treatment of patients with diseases of nervous system
15. Galantamine: Additional benefits to patients with Alzheimer's disease
16. Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors
17. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
18. Efficacy and safety of galantamine in patients with mild-tomoderate Alzheimer's disease: Multicentre randomised controlled trial
19. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep
20. Legal matters. Is it Merck or is it Pharmanex? The regulatory tale of lovatstain and Cholestin